Compare COGT & LSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | LSTR |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.3B |
| IPO Year | 2018 | 1994 |
| Metric | COGT | LSTR |
|---|---|---|
| Price | $37.08 | $151.72 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | $33.50 | ★ $153.17 |
| AVG Volume (30 Days) | ★ 1.4M | 665.9K |
| Earning Date | 05-22-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.31 |
| Revenue | $7,871,000.00 | ★ $4,743,760,000.00 |
| Revenue This Year | N/A | $6.67 |
| Revenue Next Year | $1,180.55 | $9.06 |
| P/E Ratio | ★ N/A | $48.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $119.40 |
| 52 Week High | $43.73 | $166.11 |
| Indicator | COGT | LSTR |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 47.20 |
| Support Level | $36.52 | $150.44 |
| Resistance Level | $41.02 | $162.55 |
| Average True Range (ATR) | 1.86 | 6.08 |
| MACD | -0.15 | 0.55 |
| Stochastic Oscillator | 30.69 | 42.03 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.